A Vaccine Breakthrough, Mired in Politics The approval of the first mRNA based flu vaccine marks a significant milestone in public health.
Developed by Moderna, mFlusiva boasts an impressive 27% higher efficacy rate than traditional flu vaccines.
However, beneath this scientific triumph lies a more nuanced reality: the politicization of vaccines has reached new heights.